---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008570"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:37:55.512192+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Akari shareholders approve warrant exercises and share issuances at special meeting

## Summary
- Shareholders voted overwhelmingly to approve exercisability of Series G, Placement Agent, Pre-Funded, and Note Exchange warrants.
- Proposals covered up to ~10M ADSs from Series G/Placement Agent warrants and ~19M ADSs from Pre-Funded/Note Exchange warrants.
- All five resolutions passed with over 99% of votes cast in favor; abstentions negligible.
- Meeting held March 2, 2026; matters related to capital raises and note exchanges from Dec 2025 and Jan 2026.

## SEC filing metadata
- accession: 0001493152-26-008570
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315226008570/0001493152-26-008570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315226008570/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008570
- JSON: https://secwatch.observer/filing/0001493152-26-008570.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.